Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Sichuan University · King Chulalongkorn Memorial Hospital · +3 more institutions
Abstract
-mutated NSCLC.
-mutated stage III NSCLC without progression during or after chemoradiotherapy to receive osimertinib or placebo until disease progression occurred (as assessed by blinded independent central review) or the regimen was discontinued. The primary end point was progression-free survival as assessed by blinded independent central review.
Citation impact
- FWCI
- 105.17
- Percentile
- 100%
- References
- 40
Authors
24- SLShun LuCorresponding
Sichuan University, King Chulalongkorn Memorial Hospital, Zhejiang Cancer Hospital, Union Hospital, Cancer Hospital of Chinese Academy of Medical Sciences
- TKTerufumi Kato
King Chulalongkorn Memorial Hospital, Zhejiang Cancer Hospital, Sichuan University, Union Hospital, Cancer Hospital of Chinese Academy of Medical Sciences
- XDXiaorong Dong
Zhejiang Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Union Hospital, King Chulalongkorn Memorial Hospital, Sichuan University
- MAMyung‐Ju Ahn
Zhejiang Cancer Hospital, Sichuan University, King Chulalongkorn Memorial Hospital, Union Hospital, Cancer Hospital of Chinese Academy of Medical Sciences
- LQLe-Van Quang
Zhejiang Cancer Hospital, Union Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, King Chulalongkorn Memorial Hospital, Sichuan University
Topics & keywords
- Osimertinib
- Medicine
- Internal medicine
- Hazard ratio
- Placebo
- Oncology
- Lung cancer
- Regimen
- Good health and well-being